NCT04294667dapirolizumab pegolSLEDZPLupusprednisonePBO
…luding sustained outcomes, from the phase 3 PHOENYCS GO trial ( NCT04294667) of dapirolizumab pegol (DZP).DZP is a novel CD40L inhibitor wi…
1articles mentioning funders
1funder mentions
1distinct funders extracted
0%of mentions human-reviewed
Active filtersEntity: NCT04294667 ×
NCT04294667
This funder is selected. Its supporting articles are shown below.